Ascendis Pharma A (ASND) Total Debt (2021 - 2026)

Ascendis Pharma A has disclosed Total Debt across 6 years of filings, most recently posting $340.1 million for Q1 2026.

• Total Debt for Q1 2026 came in at $340.1 million, up 85.19% year-over-year; the trailing twelve-month figure through Mar 2026 was $340.1 million (up 85.19% YoY), and the FY2025 annual result was $746.7 million, up 35.49% from the prior year.
• Total Debt came in at $340.1 million for Q1 2026 at Ascendis Pharma A, down from $746.7 million in the prior quarter.
• In the past five years, Total Debt ranged from a high of $746.7 million in Q4 2025 to a low of $94.1 million in Q2 2023.
• The 5-year median for Total Debt is $184.9 million (2024), against an average of $267.6 million.
• Across the five-year window, Total Debt surged 363.51% in 2022 and declined 29.19% in 2023, its largest moves.
• Ascendis Pharma A's Total Debt stood at $556.6 million in 2022, then slipped by 29.19% to $394.1 million in 2023, then surged by 39.84% to $551.1 million in 2024, then jumped by 35.49% to $746.7 million in 2025, then tumbled by 54.46% to $340.1 million in 2026.
• The last three Total Debt figures came in at $340.1 million (Q1 2026), $746.7 million (Q4 2025), and $273.3 million (Q3 2025), per Business Quant data.